Pfizer Inc., a prominent global pharmaceutical company, has been given a Neutral rating by UBS. The company's net sales are primarily driven by its diverse range of products.

The largest portion of sales, accounting for 52.3%, comes from primary care products, which include internal medicine medications, vaccines, treatments for Covid-19, antivirals, and mRNA-based products.

Specialty care products contribute 25.6% of net sales and focus on immunology, hospital treatments, and rare diseases. Oncology products make up 19.9% of sales, while the remaining 2.2% falls under other product categories.

Geographically, Pfizer's sales are distributed with 42.3% coming from the United States, 21.9% from Europe, and 33.8% from other regions, indicating the company's significant international presence.